Business Development / Commercialization Committee
Adam Elhofy, PhD
Vice President of Product Research and Collaborations, Cour Pharmaceutical
Dr. Adam Elhofy has over 14 years of scientific research experience in the areas of immunology, neuroscience, and oncology, with multiple publications and grants. He was funded by both the National Institutes of Health and the Multiple Sclerosis society as an investigator at Northwestern University Medical School. He has served in various roles from Principal Investigator of a Nanotech start-up to Chief Science officer. He developed the core technology for the Cell-Ess® line of products and aided in creating patents around novel uses of materials.
His doctoral research won him the award of the Top 5 trainee scientists by the American Association of Immunologists. Dr. Elhofy has 15 scientific publications in peer reviewed journals. He has played a variety of roles with start-up biotech companies ranging from Principal Investigator to Director of Corporate Development.
Rediscovery Life Sciences
Ed is an intellectual property expert and the founding president of EKMS, Inc., a company known for pioneering novel IP management techniques for two decades.
Ed sold EKMS to a publicly traded company in 2004, but came out of retirement to apply his licensing skills and tech transfer experience at CWR, where he will help patients access effective “new” treatments more quickly and affordably through Rediscovery Research™.
The repurposed drugs and other Rediscovery Research approaches established by Cures’s research partners are often safer, more effective and cheaper than the current Standard of Care, but there is often a gap between publication of research results and adoption of the “rediscovered” treatment in the clinic by physicians and patients. Ed works with public and private sector life sciences organizations to devise creative new business methods aimed at ensuring that life-saving therapies reach patients as soon as feasible.
Ed has presented and written extensively on licensing and IP strategy for John Wiley, Euromoney Publishing, Forbes, the Wall Street Journal, the Boston Globe, Mass High Tech, the Licensing Executives Society (LES) and the Boston Patent Lawyers’ Association. His recent book, “Innovate or Perish: Managing the Enduring Technology Company in the Global Market”, focuses on the challenge of IP management in today’s evolving innovation environment.
Managing Director, Armour Life Sciences; previous roles include SVP at Horizon Therapeutics
Mr. Metz founded Armour Life Sciences in 2019. He left Horizon Therapeutics after 10 years, most recently as SVP global business operations and general manager Europe. He was responsible for the administration of global business operations and corporate external affairs including patient advocacy. Mr. Metz has over 27 years of commercial, external affairs, finance, administration and operations experience in both small and large pharmaceutical and biotechnology organizations. Prior to joining Horizon Pharma, Mr. Metz’s most recent position was vice president, commercial operations for IDM Pharma who manufactured MEPACT® for pediatric osteosarcoma. Mr. Metz played a key role in the turnaround and eventual sale of IDM Pharma to Takeda Pharmaceuticals in June 2009. He led commercial efforts, including development of key opinion leader and institution center outreach, patient advocacy relations and pricing and reimbursement programming throughout pan-European markets. Prior to joining IDM Pharma, Mr. Metz led commercial operations for NeoPharm, a public rare disease oncology biotechnology company with a phase 3 compound for glioblastoma multiforme.
For nearly 13 years, Mr. Metz worked in areas of increasing responsibility at Searle and Pharmacia focusing on product introductions on several products, including Celebrex®, Arthrotec®, Daypro® and Detrol LA®. His professional experience encompassed sales, business analysis, business development, commercial operations, human resources, information technology, project management, government, public and external affairs and real estate management. In his commercial management roles, Mr. Metz directed multifunctional, operational and performance aspects of sales organizations spanning over 650 sales and support employees with overall sales totaling over $2 billion. Mr. Metz has also held sales and marketing positions at Medpointe Pharma and Reliable Biopharmaceuticals. Mr. Metz has a bachelor’s degree in management/economics with a minor in political science from Marietta College in Marietta, OH.
Norbert Riedel, PhD
Executive Chairman, Aptinyx
Dr. Riedel is president and CEO of Aptinyx, as well as a member of the company’s board of directors. He was formerly president and CEO of Naurex, the predecessor company acquired by Allergan and from which Aptinyx and its technology were spun out. Prior to Naurex, Dr. Riedel served various roles at Baxter International including corporate vice president and chief science and innovation officer. Previously, Dr. Riedel was head of worldwide biotechnology and held a number of scientific management positions at Hoechst Marion Roussel (now Sanofi). Dr. Riedel serves on the boards of Jazz Pharmaceuticals and the Illinois Biotechnology Industry Organization.
Dr. Riedel is a member of the Austrian Academy of Sciences and was appointed by Governor Pat Quinn to serve on the Illinois Innovation Council. Dr. Riedel received a Diploma and Ph.D. from the University of Frankfurt and was a postdoctoral fellow at Harvard University. Dr. Riedel is an adjunct professor at Boston University School of Medicine and Northwestern University’s Feinberg School of Medicine. Prior to moving into industry, he was an assistant professor and associate professor of medicine at Boston University School of Medicine and a visiting professor at the Massachusetts Institute of Technology.
Michael S. Rosen
Rosen BioScience Strategies
Michael S. Rosen is Senior Vice President, New Business Development for the Science + Technology Group at Forest City Enterprises, a NYSE-traded national real estate development company which develops and builds bioscience parks across the U.S. Mr. Rosen works with key research universities affiliated with Forest City bioparks, such as Northwestern University in Chicago, Johns Hopkins University in Baltimore and MIT in Boston, and endeavors to bring life science companies from Europe, Asia, Latin America, India, Israel, and Canada into these parks.
During his thirty-nine years in the life sciences industry, he held management positions with Pfizer, Bristol-Myers Squibb and Searle/Monsanto, while living in Japan, Latin America, and Europe, and worked extensively in Canada, Israel, and Asia. Mr. Rosen has been President/CEO of European and U.S. biotech and medical device companies; he founded Rosen Bioscience Management to provide CEO services to start-up life science companies including a Univ. of Wisconsin diagnostics company developing biomarkers for kidney disease, a Univ. of Illinois company developing new cancer vaccines and a woundcare company from Michael Reese Hospital. He was President/CEO of the cancer products company Endorex which he listed on the Amex. Prior to that, he was CEO of the cancer products company PharmaMar located in Madrid, Spain and Cambridge, Mass. Mr. Rosen is a founder, former Vice-Chairman and current board member of the Illinois Biotechnology Industry Organization (IBIO) and co-chairman of the board of the predecessor organization, the Chicago Biotechnology Network Association. In addition to IBIO, Mr. Rosen is a member of the board and Sr. Vice-President of the America-Israel Chamber of Commerce – Chicago, and co-chairs its Life Science Practice Group. He is a member of the Industry Advisory Board for Northwestern University’s Masters of Biotechnology Program as well as Professor of International Management and Marketing at Lake Forest Graduate School of Management; where he has led their annual program in Brazil (at the Business School of Sao Paulo) for the last 7 years.
He received his B.A. in Sociology and International Relations from Beloit College and an M.B.A. in International Business from the University of Miami and graduate studies at Northwestern University – Kellogg School of Business, Sophia University (Tokyo, Japan) and Universidad Tecnica Federico Santa Maria (Santiago, Chile)
Adriann is CEO of Vetigenics. Previously, Adriann was CEO at Orsenix, an Entrepreneur in Residence at Fortress Biotech, a public biotech company which finds and forms subsidiary companies around promising drugs and technologies. For more than 25 years, Adriann has been a global biotech and pharmaceutical industry leader managing all stages of drug development, commercialization, strategic deal-making and partnerships. Prior to Fortress Biotech, Adriann was Executive Vice President, Chief Commercial Officer of Kadmon Corporation leading Kadmon’ s commercial organization, Kadmon Pharmaceuticals, from its inception in September 2010.
Before Kadmon, Adriann was Executive Vice President, Business Development and Strategic Planning at King Pharmaceuticals where she led many profitable transactions in addition to creating and implementing King’s Corporate Strategy for Growth in 2005, contributing to the company’s overall success and ultimate sale to Pfizer in 2011.
After starting her career as a sales representative at Sterling Drug, Adriann progressed through a series of management and executive roles with established biopharmaceutical companies including Symphogen, Merck, BMS and Roche in commercial operations, strategy and corporate development. Although she’s made many important contributions in the areas of oncology, transplantation and hepatology, her leadership of many successful new product launches including leading the team responsible for the refiling and ultimate launch of ERBITUX® (cetuximab), for the treatment of cancer are testimony to her unique abilities, commitment and tenacity to “make a difference”.
Throughout her professional career, Adriann has maintained an active role with the many industry associations. In 2008, she was voted as one of the top 100 Most Inspiring People in Healthcare by PharmaVoice Magazine, in 2016 to the Business Advisory Board of Cures Within Reach and in 2014 as a member of the Springboard Life Sciences Council Executive Board. She is also a board member, strategic advisor and mentor to many start-up biotech companies. Adriann holds an MBA in Marketing and Finance from the Keller Graduate School of Management and a BS in Pre-Veterinary Medicine from the University of Delaware.
Recordati Rare Diseases
Eric Waehner is the Vice President, Business Development at Recordati Rare Diseases. He has over 25 years of life science industry experience, driving growth strategies and completing transactions across the pharmaceutical, diagnostic and medical device industry segments. Prior to joining Recordati Rare Diseases, he gained experience and contributed to portfolio growth and rationalization at Takeda Pharmaceuticals, Astellas Pharmaceuticals and Abbott Laboratories. Additionally, he gained experience as a consultant with Deloitte and RM Consulting International.
Mr. Waehner received his B.S. in Industrial Engineering from Georgia Tech and his M.B.A from Northwestern University.